Risk of dying from early prostate cancer is low regardless of treatment, study findsBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4984 (Published 15 September 2016) Cite this as: BMJ 2016;354:i4984
- Caroline White
The risk of dying from early stage prostate cancer, detected by a prostate specific antigen (PSA) test, is very low—no more than 1% over 10 years—irrespective of whether the tumour is treated with surgery, radiotherapy, or active monitoring, concludes a study published in the New England Journal of Medicine.1
The results of the Prostate Testing for Cancer and Treatment (ProtecT) study show that National Institute for Health and Care Excellence (NICE) guidance on risk stratification for treatment may need to be revised, said the investigators.
The study involved 82 429 symptomless men aged 50 to 69, drawn from UK general practice lists and given a PSA test from 1999 to 2009. Localised prostate cancer was diagnosed in 2664 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial